In vivo gene therapy

Ensoma is a preclinical in vivo gene therapy company that is focused on the targeting and editing of hematopoietic stem cells. The foundation envisions a future in which the company's technology could create a single shot HIV cure.
  • Domain
  • Investment type
    Direct equity
  • Status
  • Initial investment
    Series B
  • Partnered in
  • Investment lead
    Vanessa Bhark
  • Headquarters
  • Program strategy

More about our work

Our focus

Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.

Investment approach

Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.

Our team

We bring depth of experience to every investment, with a proven track record across sectors and scale.